The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
about
The endocannabinoid system as a target for the treatment of neurodegenerative disease.The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ anThe therapeutic potential of cannabinoids for movement disorders.Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's diseasePromising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionCannabinoids and Dementia: A Review of Clinical and Preclinical Data.Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a StressorProspects for cannabinoid therapies in basal ganglia disorders.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Endocannabinoid modulation of dopaminergic motor circuits.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Cannabinoid signaling in health and disease.Endocannabinoid system in neurodegenerative disorders.Cannabinoids for the Treatment of Movement Disorders.Cannabinoids in Parkinson's DiseaseThe bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry.Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.
P2860
Q34098196-BD45C47D-3F95-4FE3-A2AE-002C6ABABF7AQ34267133-97B7FBC2-0A8F-4593-950B-7E1772A58778Q35171113-609FFCCB-4431-4A8B-8F36-7AAB63C3BFA6Q35193305-98AF8AEA-9268-4774-9062-64630B030160Q35499568-89310DBB-0639-4831-ADF3-40EF0EB692CAQ36155898-7DD8CF77-DF9E-4422-BA00-B1A7D6203A1AQ37088001-21D83D76-6BF1-4096-998C-EF4CC86B8409Q37872326-CCE2B290-9C9B-44A9-8063-28527B06C263Q37924629-05FFFBEE-1143-49B0-ABFE-8EED3315EE18Q38018946-347C116D-4ED5-4C54-AAA0-C1E9BFF57E20Q38207680-A6E18AF1-0CCE-4A94-BA76-9721364D8E2EQ38522769-92C57B26-4FFB-40F2-8054-FE90BDBF492EQ39163671-8F99BF44-EC9C-41CC-9267-489EF1F9D803Q39368845-CCE13059-8BE6-4E55-B0ED-228BCEBEE6BAQ40701861-99B411E9-2C33-494F-89B4-6ADC56E80BD2Q42258332-B2857F93-E8D2-4522-AAEF-FFAD8F5E1276Q42495608-B02038AF-8C43-4BEB-9C22-E02AA9AB0BA3Q43162071-06532EB1-E1C0-46D4-A341-03EB662D7040Q46332293-0C6D4E47-3453-43B3-A575-48572AFEB015Q48407695-66B07226-DFE0-4555-91D8-DB5C5C053998Q53059036-AE575965-371E-44FD-B284-167589ACE6DF
P2860
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The CB(1) antagonist rimonaban ...... model of Parkinson's disease.
@en
type
label
The CB(1) antagonist rimonaban ...... model of Parkinson's disease.
@en
altLabel
The CB1 antagonist rimonabant ...... l model of Parkinson's disease
@en
prefLabel
The CB(1) antagonist rimonaban ...... model of Parkinson's disease.
@en
P2093
P1476
The CB(1) antagonist rimonaban ...... model of Parkinson's disease.
@en
P2093
P304
P356
10.1016/J.BBR.2009.04.035
P407
P577
2009-05-03T00:00:00Z